These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
11. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780 [TBL] [Abstract][Full Text] [Related]
12. [Tumor rejection antigen and cancer immunotherapy]. Matsutake T; Nakayama E Gan To Kagaku Ryoho; 1995 Nov; 22(13):1871-7. PubMed ID: 7487115 [TBL] [Abstract][Full Text] [Related]
13. Strategies to overcome obstacles to successful immunotherapy of melanoma. Pandolfi F; Cianci R; Lolli S; Dunn IS; Newton EE; Haggerty TJ; Boyle LA; Kurnick JT Int J Immunopathol Pharmacol; 2008; 21(3):493-500. PubMed ID: 18831916 [TBL] [Abstract][Full Text] [Related]
14. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767 [TBL] [Abstract][Full Text] [Related]
15. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice. Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614 [TBL] [Abstract][Full Text] [Related]
17. Tumor antigen targets and tumor immunotherapy. Mufson RA Front Biosci; 2006 Jan; 11():337-43. PubMed ID: 16146735 [TBL] [Abstract][Full Text] [Related]
18. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946 [TBL] [Abstract][Full Text] [Related]
19. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Rosenberg SA Annu Rev Med; 1996; 47():481-91. PubMed ID: 8712798 [TBL] [Abstract][Full Text] [Related]
20. Molecular genetic and immunotherapeutic targets in metastatic melanoma. Melis C; Rogiers A; Bechter O; van den Oord JJ Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]